Official pages and third-party coverage in one index.
tullisfunds.com12 items across 11 mapped pages · Crawled Sep 24, 2026
Official pages and third-party coverage in one index
First ever prospective randomized multicenter clinical utility study shows the favorable impact of AVISE® Lupus on clinical decision-making and patient management SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today … Continue reading "Exagen Announces Public
Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.
A hematologist-oncologist, Barbara is Professor of Medicine at Harvard Medical School and the Brigham and Women’s Hospital (BWH). She co-founded and now leads the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a collaborative effort to improve standards for the ethics, conduct, and regulatory environment of international clinical trials. In this capacity, she works with regulators around the world, major pharmaceutical companies, biotech, clinical research organizations,
David participates in and often leads the scientific and clinical portions of the Tullis investment process. He is also chair of the THI Advisory Board.
Melanie coordinates communications with limited partners and manages fundraising administration. Prior to rejoining Tullis in 2018, Melanie provided marketing communications services to clients in the finance and healthcare industries for seven years, served as a marketing manager for HealthSouth Corporation, and was director of corporate communications for Professional Sports Care Management. Before that, she worked for Tullis for 14 years.
As a fund controller, Naseer has numerous accounting and finance responsibilities. Prior to joining the Tullis team in 2020, he worked as a Senior Accountant for a private equity firm in the industrial space and as a state-level tax auditor. Naseer holds a Bachelor of Science in accounting and finance from York College of Pennsylvania and a Master of Business Administration with a concentration in finance from Lynn University.
We are a pioneer in healthcare-focused growth capital – and an experienced, specialized commercial-stage healthcare investment manager. Our team is committed to generating superior returns by investing in people, products, technologies and services that create a brighter future for global health.
To learn more about Tullis Health Investors or to provide us with information regarding an investment opportunity, please contact us.
Tullis Health Investors is a private equity firm that partners with high-growth, commercial-stage healthcare companies and invests in the medical device, healthcare services and technology, specialty pharmaceuticals, and biotechnology sectors. Our investments in people, products, technologies, and services have a significant impact on global health.
Tullis Health Investors is a private equity firm that partners with high-growth, commercial-stage healthcare companies and invests in the medical device, healthcare services and technology, specialty pharmaceuticals, and biotechnology sectors. Our investments in people, products, technologies, and services have a significant impact on global health.
